Corante

About this author
Zack Lynch is author of The Neuro Revolution: How Brain Science Is Changing Our World (St. Martin's Press, July 2009).
He is the founder and executive director of the Neurotechnology Industry Organization (NIO) and co-founder of NeuroInsights. He serves on the advisory boards of the McGovern Institute for Brain Research at MIT, the Center for Neuroeconomic Studies, Science Progress, and SocialText, a social software company. Please send newsworthy items or feedback - to Zack Lynch.
Follow me on Twitter at @neurorev
Receive by email

GUEST AUTHOR ARCHIVES
THE NEURO REVOLUTION
TNRCoverWeb120.jpg Buy on Amazon
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

Brain Waves

« Neurotechnology Industry Research | Main | Connect the Dots »

February 23, 2005

FDA Clears MDMA Trial for Post Traumatic Stress Disorder

Email This Entry

Posted by Zack Lynch

Post-traumatic Stress Disorder (PTSD) is a psychiatric disorder that can occur following the experience or witnessing of life-threatening events such as military combat, natural disasters, terrorist incidents, serious accidents, or violent personal assaults. People who suffer from PTSD often relive the experience through nightmares and flashbacks, have difficulty sleeping, and feel detached or estranged, and these symptoms can be severe enough and last long enough to significantly impair the person's daily life.

In an effort to help traumatized American soldiers the Guardian reports that the US Food and Drug Administration has given the green light for the soldiers to be included in an experiment to see if MDMA, the active ingredient in ecstasy, can treat post-traumatic stress disorder.

"Scientists behind the trial in South Carolina think the feelings of emotional closeness reported by those taking the drug could help the soldiers talk about their experiences to therapists. Several victims of rape and sexual abuse with post-traumatic stress disorder, for whom existing treatments are ineffective, have been given MDMA since the research began last year.

Michael Mithoefer, the psychiatrist leading the trial, said: "It's looking very promising. It's too early to draw any conclusions but in these treatment-resistant people so far the results are encouraging. "People are able to connect more deeply on an emotional level with the fact they are safe now."

According to the National Center for PSTD up to 30% of combat veterans suffer from the condition at some point in their lives. If these trials prove to be effective for veterans, it would be wise to open up this effective emoticeutical tool to the broader global public quickly.

Update: 1/3 of active and retired police in the US suffer from PSTD. For more info please see tearsofacop

Comments (1) + TrackBacks (0) | Category: Emoticeuticals


COMMENTS

1. Heather Lynn Lieber on February 24, 2005 11:44 PM writes...

I BELIEVE THAT EXTASY COULD BENIFIT THE CLIENT WHO'S SUFFERING FROM PTSD. I MYSELF AM A SUFFERER OF THE DISORDER AND SO FAR, NOTHING HAS HELPED ME OPEN UP MY REAL FEELINGS OF WHAT HAPPENED TO ME WHEN I WAS YOUNGER. I FEEL THAT EMOTIONAL CLOSENESS COMBINED WITH ONE-ON-ONE THERAPY WOULD BE A GOOD THING TO TRY. I'D VOTE FOR IT ANY DAY.

WRITE TO ME.
HEATHER LIEBER PLASHTEN@HOTMAIL.COM

Permalink to Comment


EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Chinese Cover of The Neuro Revolution
The Neuro Revolution Lands In China
How Neuroscience Will Change the World - My Interview on Reason.tv
Neuroscience Hearing on Capitol Hill Wednesday Sept 29, 2pm
The Neuro Revolution Published in Japan as "Neuro Wars"
Neurotech 2010: Translational Researchers Highlight Innovation
The Neuro Revolution in China Progressing
Speakers for Neurotech 2010 - Boston, May 19-20